Search / Trial NCT06612671

Treatment Outcomes of Retroperitoneal Sarcoma

Launched by TAICHUNG VETERANS GENERAL HOSPITAL · Sep 22, 2024

Trial Information

Current as of October 04, 2024

Unknown status

Keywords

Retroperitoneal Sarcoma Surgery Radiotherapy

Description

Retroperitoneal Sarcoma (RPS) which is a rare disease which incidence is 1.79/100,000. The treatment is difficult to due to it anatomy position which often invade to multiple organs and cause the complete surgical resection to be very complex and difficult. It was known to sacrifice one side kidney will improve the resection rate. To this days, successful surgical resection was still the gold standard that provide most benefit in overall survival. To reach that goal, pre-operative radiotherapy was applied to RPS which intended to achieve similar effect in rectal cancer for the down staging ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * the patient who have retroperitoneal maliganacy and receive complete tumor excision in our hospital
  • Exclusion Criteria:
  • * the patient did not receive complete tumor excision in our hospital
  • * the pathological report yielded not malignancy tumor

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Taichung, , Taiwan

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0